BCLI
Income statement / Annual
Last year (2024), Brainstorm Cell Therapeutics Inc.'s total revenue was $849.00 K,
and the percentage change from the previous year is not available.
In 2024, Brainstorm Cell Therapeutics Inc.'s net income was $11.62 M.
See Brainstorm Cell Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$849.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$366.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$265.00 K
|
$285.00 K
|
$260.00 K
|
$219.00 K
|
$366.00 K
|
$110.00 K
|
$85.00 K
|
$77.00 K
|
$87.00 K
|
| Gross Profit |
$849.00 K
|
-$265.00 K
|
-$285.00 K
|
-$260.00 K
|
-$219.00 K
|
-$732.00 K
|
-$110.00 K
|
-$85.00 K
|
-$77.00 K
|
-$87.00 K
|
| Gross Profit Ratio |
1
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$0.00
|
$10.48 M
|
$13.96 M
|
$15.24 M
|
$22.33 M
|
$17.20 M
|
$8.29 M
|
$977.00 K
|
$2.25 M
|
$4.95 M
|
| General & Administrative Expenses |
$0.00
|
$10.69 M
|
$10.87 M
|
$9.30 M
|
$9.36 M
|
$5.80 M
|
$5.77 M
|
$4.02 M
|
$2.83 M
|
$3.59 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$0.00
|
$10.69 M
|
$10.87 M
|
$9.30 M
|
$9.36 M
|
$5.80 M
|
$5.77 M
|
$4.02 M
|
$2.83 M
|
$3.59 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$0.00
|
$21.17 M
|
$24.82 M
|
$24.54 M
|
$31.68 M
|
$23.00 M
|
$14.06 M
|
$5.00 M
|
$5.08 M
|
$8.54 M
|
| Cost And Expenses |
$0.00
|
$21.44 M
|
$24.82 M
|
$24.54 M
|
$31.68 M
|
$23.00 M
|
$14.06 M
|
$5.00 M
|
$5.08 M
|
$8.54 M
|
| Interest Income |
$0.00
|
$0.00
|
$545.00 K
|
$82.00 K
|
$127.00
|
$252.00
|
$0.00
|
$47.00 K
|
$101.00 K
|
$48.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$265.00 K
|
$285.00 K
|
$260.00 K
|
$219.00 K
|
$164.00 K
|
$110.00 K
|
$85.00 K
|
$77.00 K
|
$87.00 K
|
| EBITDA |
$0.00 |
-$16.93 M |
-$23.99 M |
-$24.28 M |
-$31.47 M |
-$23.09 M |
-$13.84 M |
-$4.87 M |
-$4.91 M |
-$8.40 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
63.08
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
62.84
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$0.00
|
$4.25 M
|
$545.00 K
|
$82.00 K
|
-$127.00 K
|
-$252.00 K
|
$115.00 K
|
$47.00 K
|
$101.00 K
|
$48.00 K
|
| Income Before Tax |
$11.62 M
|
-$17.19 M
|
-$24.28 M
|
-$24.46 M
|
-$31.81 M
|
-$23.25 M
|
-$13.95 M
|
-$4.95 M
|
-$4.98 M
|
-$8.49 M
|
| Income Before Tax Ratio |
13.69
|
0
|
0
|
0
|
0
|
63.53
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
$11.62 M
|
-$17.19 M
|
-$24.28 M
|
-$24.46 M
|
-$31.81 M
|
-$23.25 M
|
-$13.95 M
|
-$4.95 M
|
-$4.98 M
|
-$8.49 M
|
| Net Income Ratio |
13.69
|
0
|
0
|
0
|
0
|
63.53
|
0
|
0
|
0
|
0
|
| EPS |
2.19 |
-0.4 |
-0.66 |
-0.68 |
-1.07 |
-1.07 |
-0.69 |
-0.26 |
-0.27 |
-0.46 |
| EPS Diluted |
2.19 |
-0.4 |
-0.66 |
-0.68 |
-1.07 |
-1.07 |
-0.69 |
-0.26 |
-0.27 |
-0.46 |
| Weighted Average Shares Out |
$5.31 M
|
$42.98 M
|
$36.51 M
|
$36.18 M
|
$29.85 M
|
$21.91 M
|
$20.00 M
|
$18.78 M
|
$18.66 M
|
$18.41 M
|
| Weighted Average Shares Out Diluted |
$5.31 M
|
$43.08 M
|
$36.51 M
|
$36.18 M
|
$29.85 M
|
$21.91 M
|
$20.00 M
|
$18.78 M
|
$18.66 M
|
$18.41 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
